Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia.

IF 2 4区医学 Q3 HEMATOLOGY

Hematology Pub Date : 2024-12-01 Epub Date: 2023-12-14 DOI:10.1080/16078454.2023.2293494

Yu Cui, Ruihua Mi, Lin Chen, Lin Wang, Dongbei Li, Xudong Wei

{"title":"Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia.","authors":"Yu Cui, Ruihua Mi, Lin Chen, Lin Wang, Dongbei Li, Xudong Wei","doi":"10.1080/16078454.2023.2293494","DOIUrl":null,"url":null,"abstract":"Objectives: Acute undifferentiated leukemia (AUL) is a clinical rare leukemia with an overall poor prognosis. Currently, there are no well-established treatment guidelines for AUL, further exploration of optimal treatment options is now required.Methods: We report an AUL patient who was complicated by a NRAS mutation and del5q was admitted to our hospital and we present the clinical features. In addition, we conducted a literature review.Results: The \"VA\" scheme combines agents Venetoclax and Azacitidine that have synergistic therapeutic effect with a tolerable safety profile. There is no previous report of the \"VA\" scheme employed in AUL treatment. An AUL patient who was complicated by a NRAS mutation and del5q was admitted to our hospital. The \"VA\" scheme was administrated, and complete remission (CR) was achieved at the end of the first cycle. The patient then underwent HLA-identical sibling allogeneic hematopoietic stem cell transplantation.Discussion: The \"VA\" scheme has been extensively used in AML treatment, but its application in AUL treatment has not yet been reported. This study is the first to report an AUL patient treated with the \"VA\" scheme and achieved CR. Our result preliminarily suggested the effectiveness and safety of the \"VA\" scheme in AUL treatment, but validation is required in more clinical samples. The \"VA\" scheme provides a new treatment option for AUL patients and deserves further clinical promotion.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/16078454.2023.2293494","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Acute undifferentiated leukemia (AUL) is a clinical rare leukemia with an overall poor prognosis. Currently, there are no well-established treatment guidelines for AUL, further exploration of optimal treatment options is now required.

Methods: We report an AUL patient who was complicated by a NRAS mutation and del5q was admitted to our hospital and we present the clinical features. In addition, we conducted a literature review.

Results: The "VA" scheme combines agents Venetoclax and Azacitidine that have synergistic therapeutic effect with a tolerable safety profile. There is no previous report of the "VA" scheme employed in AUL treatment. An AUL patient who was complicated by a NRAS mutation and del5q was admitted to our hospital. The "VA" scheme was administrated, and complete remission (CR) was achieved at the end of the first cycle. The patient then underwent HLA-identical sibling allogeneic hematopoietic stem cell transplantation.

Discussion: The "VA" scheme has been extensively used in AML treatment, but its application in AUL treatment has not yet been reported. This study is the first to report an AUL patient treated with the "VA" scheme and achieved CR. Our result preliminarily suggested the effectiveness and safety of the "VA" scheme in AUL treatment, but validation is required in more clinical samples. The "VA" scheme provides a new treatment option for AUL patients and deserves further clinical promotion.

查看原文本刊更多论文

病例报告：Venetoclax 联合阿扎胞苷治疗急性未分化白血病。

目的：急性未分化白血病（AUL）是一种临床罕见的白血病，总体预后较差。目前，急性未分化白血病尚无成熟的治疗指南，需要进一步探索最佳治疗方案：我们报告了本院收治的一名因 NRAS 突变和 del5q 而并发的 AUL 患者，并介绍了其临床特征。此外，我们还进行了文献综述：VA "方案结合了 Venetoclax 和阿扎胞苷两种药物，具有协同治疗效果和可耐受的安全性。目前还没有关于将 "VA "方案用于AUL治疗的报道。我院收治了一名因NRAS突变和del5q而复杂化的AUL患者。患者接受了 "VA "方案治疗，并在第一个周期结束时获得了完全缓解（CR）。随后，患者接受了HLA同种异体造血干细胞移植：讨论："VA "方案已广泛应用于急性髓细胞性白血病的治疗，但其在急性髓细胞性白血病治疗中的应用尚未见报道。本研究首次报道了一名接受 "VA "方案治疗并获得 CR 的 AUL 患者。我们的研究结果初步证明了 "VA "方案在 AUL 治疗中的有效性和安全性，但还需要在更多的临床样本中进行验证。VA "方案为AUL患者提供了一种新的治疗选择，值得进一步临床推广。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology 医学-血液学

CiteScore

2.60

自引率

5.30%

发文量

140

审稿时长

3 months

期刊介绍： Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Of the fixed sections, annotations are accepted on any general or scientific field: technical annotations covering current laboratory practice in general hematology, blood transfusion and clinical trials, and current clinical practice reviews the consensus driven areas of care and management.